Logo
Contact    |    Site Map    |    Careers

News & Publications

Acetylon Presents at the Wells Fargo Celgene Partnership Forum

FOR IMMEDIATE RELEASE

BOSTON – January 21, 2015 – Acetylon Pharmaceuticals, Inc., the leader in the development of selective histone deacetylase (HDAC) inhibitors for enhanced therapeutic outcomes, today announced that Walter C. Ogier, President and Chief Executive Officer of Acetylon, participated in the Wells Fargo Celgene Partnership Forum. Mr. Ogier discussed Acetylon’s pipeline of selective HDAC inhibitors this morning on the panel entitled, “Express Yourself: Using Epigenetics to Transform Cancer Treatment.” In addition, Mr. Ogier gave a presentation highlighting the positive preclinical and clinical data presented at the 2014 American Society of Hematology Annual Meeting and the progression of Acetylon’s lead HDAC6 inhibitor, ricolinostat, into Phase 2 clinical studies for the treatment of multiple myeloma and for the treatment of lymphoma.

The Wells Fargo forum highlights companies that have formed a partnership with Celgene. In 2013, Acetylon signed a strategic collaboration and option agreement with Celgene, which includes an exclusive option for the future acquisition of Acetylon by Celgene.

About Acetylon

Acetylon Pharmaceuticals, Inc., based in Boston, Massachusetts, is a leader in the development of novel small molecule drugs targeting epigenetic mechanisms for the enhancement of therapeutic outcomes in cancer and other critical human diseases. The Company’s epigenetic drug discovery platform has yielded a proprietary portfolio of optimized, orally-administered Class I and Class II histone deacetylase (HDAC) selective compounds. Alteration of HDAC regulation through selective HDAC inhibition is thought to be applicable to a broad range of diseases including cancer, sickle cell disease and beta-thalassemia, and autoimmune and neurodegenerative diseases. Acetylon’s lead drug candidate, ricolinostat (ACY-1215), is a selective HDAC6 inhibitor currently in Phase 2 clinical development for the treatment of multiple myeloma. The Company recently announced a strategic collaboration agreement with Celgene Corporation, which includes an exclusive option for the future acquisition of Acetylon by Celgene. Acetylon’s scientific founders are affiliated with Harvard University, the Dana-Farber Cancer Institute, the Massachusetts General Hospital, and Harvard Medical School. www.acetylon.com

 


CONTACT:
Acetylon

Walter C. Ogier
President and Chief Executive Officer
(617) 435-1300
wogier@acetylon.com

 

MEDIA:
MacDougall Biomedical Communications
(781) 235-3060

Kari Watson
kwatson@macbiocom.com

Michelle Avery
mavery@macbiocom.com

 

Back